Epizyme Testing New Mesothelioma Treatment with Phase Two Clinical Trial
Biopharmaceutical company Epizyme, Inc. is starting a new phase two clinical trial using tazemetostat as a treatment for mesothelioma cancer.
Biopharmaceutical company Epizyme, Inc. is starting a new phase two clinical trial using tazemetostat as a treatment for mesothelioma cancer.
A new drug has been granted Orphan Drug Status by the US FDA as a potentially safe and effective treatment for mesothelioma cancer.